Does lamivudine Monotherapy-Based cART be Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA < 20,000 IU/mL?
This study suggests that 3TC monotherapy-based cART is efficacious for HBV treatment through 48 weeks in HIV/HBV coinfection when baseline HBV DNA <20,000 IU/mL. Studies with long-term follow-up are warranted to determine if this finding persists.
A small amount of alcohol consumption is a significant risk factor for the onset of IFG in NAFLD patients; onset risk differs according to the amount of alcohol consumption.